Scarica l'app Stockscreener
0.38
12.82%
0.0438
Dopo l'orario di chiusura:
.39
0.01
+2.63%
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché RNAZ Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$0.3362
Aprire:
$0.331
Volume 24 ore:
517.24K
Relative Volume:
0.32
Capitalizzazione di mercato:
$5.80M
Reddito:
-
Utile/perdita netta:
$-19.59M
Rapporto P/E:
-0.0156
EPS:
-24.29
Flusso di cassa netto:
$-16.49M
1 W Prestazione:
+8.40%
1M Prestazione:
-38.33%
6M Prestazione:
-69.66%
1 anno Prestazione:
-95.88%
Intervallo 1D:
$0.331
$0.388
Intervallo di 1 settimana:
$0.3144
$0.388
Portata 52W:
$0.216
$18.66
Transcode Therapeutics Inc Stock (RNAZ) Company Profile
Nome
Transcode Therapeutics Inc
Settore
Industria
Telefono
857-301-6857
Indirizzo
6 LIBERTY SQUARE, BOSTON
Confronta RNAZ con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| RNAZ | 0.38 | 5.80M | 0 | -19.59M | -16.49M | -24.29 |
| VRTX | 450.37 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 744.50 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 596.74 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.80 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 108.23 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Transcode Therapeutics Inc Borsa (RNAZ) Ultime notizie
Craig Hallum Downgrades Sow Good (NASDAQ:SOWG) to Hold - Defense World
TransCode Therapeutics (NASDAQ:RNAZ) Receives Buy Rating from HC Wainwright - Defense World
The Goldman Sachs Group Boosts Tarsus Pharmaceuticals (NASDAQ:TARS) Price Target to $41.00 - Defense World
TScan Therapeutics (NASDAQ:TCRX) Earns “Buy” Rating from HC Wainwright - Defense World
Sow Good (NASDAQ:SOWG) Lowered to Neutral Rating by Roth Mkm - Defense World
Spero Therapeutics’ (SPRO) “Overweight” Rating Reiterated at Cantor Fitzgerald - Defense World
TransCode Therapeutics Inc (RNAZ) Quarterly 10-Q Report - Quartzy
Transcode Therapeutics Reports Increased Losses Amid Funding Challenges - TipRanks
Transcode Therapeutics sends open letter to shareholders - TipRanks
TransCode Therapeutics Open Letter to Shareholders - The Manila Times
TransCode (RNAZ) Faces Delisting Risk, Seeks Shareholder Approval for Reverse Split | RNAZ Stock News - StockTitan
TransCode Therapeutics maintains Nasdaq listing with conditions - Investing.com
TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance - The Manila Times
TransCode Therapeutics maintains Nasdaq listing with conditions By Investing.com - Investing.com UK
TransCode (RNAZ) Maintains Nasdaq Listing Despite Reprimand Over Compliance Issues | RNAZ Stock News - StockTitan
TransCode advances to phase 1 cancer trial's next stage - Investing.com
ORIC® Pharmaceuticals Presents Data Further Supporting Potential Best-In-Class Profile of ORIC-114 to Treat EGFR Exon 20 Insertions and Other Atypical Mutations at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics - The Manila Times
TransCode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 TTX-MC138 Clinical Trial Following Favorable Review of Cohort 1 Safety Data - StockTitan
Form PRE 14A Transcode Therapeutics, For: Oct 15 - StreetInsider.com
TransCode Therapeutics Inc (RNAZ) is a good investment, but the stock may be undervalued - US Post News
Tevogen Bio (Nasdaq: TVGN) Stock Recovers After Major Updates - DRP Journal
TransCode Therapeutics Inc. (NASDAQ: RNAZ) Stock Sees Bullish Move: But Why? - DRP Journal
BloomZ Inc. (NASDAQ: BLMZ) Stock Rockets On a New Contract - DRP Journal
TransCode Therapeutics Inc (NASDAQ:RNAZ) stock crossing the finish line today - US Post News
TransCode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Clinical Trial with TTX-MC138, a - EIN News
There is no doubt that TransCode Therapeutics Inc (RNAZ) ticks all the boxes. - SETE News
TransCode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted Technology - The Manila Times
RNAZ’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - The InvestChronicle
TransCode Therapeutics Inc (RNAZ)’s stock chart: A technical perspective - US Post News
Halozyme (HALO) Stock Surges Amid Positive Earnings and Analyst Ratings - GuruFocus.com
TransCode Therapeutics Inc’s Market Journey: Closing Weak at 0.49, Down -15.04 - The Dwinnex
U.S. shares mixed at close of trade; Dow Jones Industrial Average down 0.21% - MSN
Riding the Waves: A Guide to Investing in RNAZ Stock - The InvestChronicle
Transcode Therapeutics faces potential Nasdaq delisting - Investing.com
TransCode Therapeutics Inc (RNAZ): Worth A Small Bite At $0.62 - Stocks Register
TransCode Therapeutics Begins Dosing Patients in Phase 1 Trial for Metastatic Cancer Therapy - Proactive Investors USA
U.S. shares mixed at close of trade; Dow Jones Industrial Average down 0.70% - MSN
TransCode Therapeutics Inc (RNAZ) expanding its growth trajectory ahead - SETE News
Gaining Ground: TransCode Therapeutics Inc (RNAZ) Closes Higher at 0.42, Up 35.75 - The Dwinnex
TransCode Therapeutics Inc (RNAZ) presents a great opportunity, but the stock is slightly undervalued - US Post News
Ratio Review: Analyzing TransCode Therapeutics Inc (RNAZ)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Taking the lead: TransCode Therapeutics Inc (RNAZ) - SETE News
Recent Insider Activity Could Benefit Ocean Power Technologies (OPTT) - Knox Daily
W.R. Berkley Corp. [WRB] Investment Appeal on the Rise - Knox Daily
TransCode begins Phase 1 trial of metastatic cancer treatment By Investing.com - Investing.com Canada
RNAZ’s Financial Health: Exploring TransCode Therapeutics Inc’s Debt-to-Equity Ratio of 1.79 - The InvestChronicle
RNAZ’s price-to-sales ratio: A comparative analysis with its peers - US Post News
TransCode begins Phase 1 trial of metastatic cancer treatment - Investing.com
TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate - StockTitan
TransCode reports progress in metastatic breast cancer treatment By Investing.com - Investing.com Australia
Transcode Therapeutics announces publication of study on TTX-MC138 - TipRanks
Transcode Therapeutics Inc Azioni (RNAZ) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.93%
3.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):